Q32 Bio tumbles after mid-stage trial setback for dermatitis drug

Q32 Bio

11/12/2024 13:23

** Shares of drug developer Q32 Bio  QTTB.O  fall 65.3% to
$8.46 premarket
    ** QTTB, late on Tuesday, said its experimental drug
bempikibart failed to meet the main goal in a part of a
mid-stage trial studying it in patients with atopic dermatitis
    ** The two-part trial was evaluating the drug in adults with
atopic dermatitis, a condition that causes dry, itchy and
inflamed skin
    ** Co plans to conduct a review to better understand the
results 
    ** Up to last close, stock has more than doubled YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))